Nationwide Clinical Study Expands Platform to Test Medications to Treat Mild-to-Moderate COVID-19
Web and phone-based enrollment allows people anywhere in the United States diagnosed with COVID-19 as outpatients to help test potential COVID-19 treatments without leaving home.
DCRI Think Tank Suggests Approach for Incorporating Patient-Reported Outcome Measures into Clinical Trials
A “validity argument” approach takes into account that the context of each trial is different and attempts to overcome barriers historically associated with measuring and reporting patient-reported
ABC Science Collaborative Finds Schools Are Safe, Even During COVID-19 Winter Surge; Transmission is Higher for Extracurricular Events Such as Sports
Despite a surge in community cases in winter 2020, within-school transmission remained low, with most transmission within high schools occurring in school-sponsored sports.
Increasing Health Care System Participation in Research Requires New Support Systems
DCRI Executive Director Adrian Hernandez, MD, MHS, and co-authors recently published a commentary in the New England Journal of Medicine advocating for new ways to incentivize health care systems t
Report Shows that N.C. K-12 Schools Reopened Safely, Paving the Way for Schools Nationwide to Limit COVID-19 Spread in the Classroom
Top scientists and physicians from the ABC Science Collaborative have shared insights from North Carolina schools, coupled with a science-based blueprint for all schools to resume full, in-person i
DCRI and HumanFirst Collaborate to Improve Scientific Rigor for Digital Measures
The new Digital Measures Evaluation Center will evaluate digital sensors and other measures, a critical step to ensure products are evaluated for both accuracy and equity.
Randomized, Pragmatic Trial Testing Antimicrobial Therapy for Treatment of Idiopathic Pulmonary Fibrosis Shows No Significant Effect
What ADAPTABLE Has Taught Us
Following the presentation of results from DCRI’s ADAPTABLE
ACC 2021: CONNECT-HF Provides New Data on Heart Failure Quality Improvement
ACC 2021: ACTION Trial Shows Oral Anticoagulation with Rivaroxaban Does Not Help Patients With COVID-19
The investigators found no significant benefit to patient outcomes when examining time to death, duration of hospitalization, or duration of supplemental oxygen.